Dishman Carbogen Amcis Share News - Latest Updates, Live News & More

Latest news about Dishman Carbogen Amcis

Dishman Carbogen Amcis Q2 Net Profit Doubles Despite Revenue Decline 4 days ago

Dishman Carbogen Amcis Ltd, a CDMO sector player, reported a 97% year-over-year increase in Q2 net profit to 652.70 million rupees, despite a 17.20% revenue decline to 6.53 billion rupees. The company's EBITDA marginally increased to 1.49 billion rupees, with EBITDA margin expanding to 22.81% from 18.65%. This performance demonstrates improved operational efficiency and effective cost management in challenging market conditions.

Dishman Carbogen Amcis to Announce Q2 FY26 Results, Schedules Earnings Call 8 days ago

Dishman Carbogen Amcis Streamlines Operations: Merges Two Swiss Subsidiaries Oct 16, 2025

Dishman Carbogen Amcis Subsidiary Forms Strategic Alliance with Celonic Group for Integrated ADC Platform Oct 07, 2025

Dishman Carbogen Amcis Boosts Authorized Share Capital by Rs. 3.95 Crores Sep 19, 2025

More news about Dishman Carbogen Amcis

05Sept 25

Dishman Carbogen Amcis Reports Strong Revenue Growth and Improved Financial Position

Dishman Carbogen Amcis Limited, a global CDMO, reported robust financial results for LTM Q1 FY26. Revenue reached INR 28,958.00 million with a 9.10% CAGR from FY21 to FY25. The company maintained a healthy EBITDA margin of 20.10% and a contribution margin of 81.60%. With an order book of INR 23,094.00 million for FY26 and over 200 global customers, the company shows promising growth potential. Operating across 10 global manufacturing sites, Dishman Carbogen Amcis specializes in high-value areas like high potency APIs and ADCs. The company's improved financial position is reflected in its reduced Net Debt to EBITDA ratio, from 5.30x in FY23 to 2.80x in LTM Q1 FY26. Strategic initiatives focus on expanding into niche high-growth areas, operational efficiency, and sustainability.

26Aug 25

Dishman Carbogen Amcis Receives US FDA Approval for Naroda Facility

Dishman Carbogen Amcis Limited has received an Establishment Inspection Report (EIR) from the US FDA for its Naroda facility, signifying successful closure of a recent inspection. The company's facilities in Bavla and Naroda in India, as well as in Switzerland and the Netherlands, maintain their US FDA approvals. This development reinforces the company's commitment to quality standards and regulatory compliance in pharmaceutical manufacturing.

19Aug 25

Dishman Carbogen Amcis Seeks Shareholder Approval for Capital Increase and Rs 1,000 Crore Fund Raise

Dishman Carbogen Amcis Limited has issued a postal ballot notice for shareholder approval on five key resolutions. The company plans to increase its authorized share capital from Rs 34.05 crore to Rs 38.00 crore by creating 1.97 crore additional equity shares. It aims to raise up to Rs 1,000.00 crore through various means for debt repayment and corporate purposes. The company is also seeking approval for the reappointment of Mrs. Deohooti J. Vyas as Whole-time Director and the appointment of Mr. Dhaval Rameshchandra Shah as a Non-Executive Director. E-voting is scheduled from August 21 to September 19, 2025, with results expected by September 22, 2025.

13Aug 25

Dishman Carbogen Amcis Reports Strong Q1 Results, Approves ₹10,000 Crore Fundraising

Dishman Carbogen Amcis Limited (DCAL) reported a net profit of ₹23.41 crores in Q1, reversing a loss of ₹77.57 crores from the previous year. Total income increased by 35.2% to ₹708.05 crores. The company approved fundraising up to ₹10,000 crores and increased its authorized share capital. Board changes include re-appointment of Mrs. Deohooti J. Vyas as Whole-time Director and appointment of Mr. Dhaval Rameshchandra Shah as Non-Executive Director. The debt-equity ratio was 0.35, and net worth increased to ₹6,183.52 crores.

13Jun 25

Dishman Carbogen Amcis Passes USFDA Inspection with Flying Colors

Dishman Carbogen Amcis successfully completed a United States Food and Drug Administration (USFDA) inspection without any observations or issuance of Form 483. This outcome indicates no issues were identified during the inspection process, demonstrating the company's high-quality standards and compliance with international regulatory requirements. The successful inspection enhances the company's credibility, potentially boosting market confidence and opening opportunities for market expansion in the U.S. pharmaceutical sector.

06Jun 25

Dishman Carbogen Amcis' Swiss Unit Secures Major Co-Investment Deal

Dishman Carbogen Amcis' Swiss subsidiary has entered into a co-investment agreement worth over CHF 25 million (₹260 crore) with a key Japanese client. The investment will be used to upgrade and expand ADC manufacturing facilities in Aarau and Neuland, Switzerland. This move aims to enhance the company's capabilities in the growing Antibody-Drug Conjugate market, potentially increasing production capacity and strengthening its market position.

22May 25

Dishman Carbogen Amcis Swings to Profit in Q4, Reports Strong Revenue Growth

Dishman Carbogen Amcis has achieved a significant financial turnaround in Q4, posting a net profit of ₹431.00 crore compared to a loss of ₹699.00 crore in the previous year. Revenue increased by 9.5% to ₹7,160.00 crore. EBITDA more than doubled to ₹1,520.00 crore, with the EBITDA margin expanding from 9.6% to 21.3%. This performance demonstrates improved operational efficiency and cost management.

22Apr 25

Dishman Carbogen Amcis Secures Milestone Drug Manufacturing License in Shanghai

CARBOGEN AMCIS (Shanghai) Co. Ltd., a wholly-owned subsidiary of Dishman Carbogen Amcis Limited, has obtained its first Drug Manufacturing License from China's National Medical Products Administration. The 40,000m² facility in Shanghai Chemical Industry Park offers early-phase R&D, pilot scale production, and commercial GMP manufacturing. With over 140 employees, the site can handle highly potent compounds up to category 3 and provide full GMP product release and analytical support. This approval strengthens the company's position in the Chinese pharmaceutical market and enhances its global outsourcing capabilities.

21Apr 25

Dishman Carbogen Amcis Secures First Drug Manufacturing License in Shanghai, Boosting China Operations

Dishman Carbogen Amcis Limited's subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has obtained its first Drug Manufacturing License from China's NMPA. The 40,000m² Shanghai facility, employing over 140 people, is equipped for early-phase R&D, pilot scale production, and commercial GMP manufacture. It can handle highly potent compounds and offers comprehensive analytical support. This approval strengthens the company's position in the Chinese pharmaceutical market and enhances its global service offerings.

11Apr 25

Dishman Carbogen Amcis Subsidiary Secures Drug Manufacturing License in Shanghai

Dishman Carbogen Amcis Limited's Shanghai-based subsidiary has obtained a drug manufacturing license from China's National Medical Products Administration (NMPA). This approval enables the company to manufacture pharmaceutical products at its Shanghai facility, potentially expanding its operations in the Chinese market. The license is expected to provide direct access to the Chinese pharmaceutical market, improve operational efficiency, and potentially drive revenue growth.

09Apr 25

Dishman Carbogen Amcis Subsidiary Secures Drug Manufacturing License in China, Expanding Asian Footprint

Dishman Carbogen Amcis Limited's wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has received a drug manufacturing license from China's National Medical Products Administration (NMPA) on April 8, 2025. This license allows the company to manufacture pharmaceutical products in China, marking a significant step in its global expansion strategy and strengthening its presence in the Asian pharmaceutical market.

24Mar 25

Dishman Carbogen Amcis' Subsidiary Secures GMP Certification for Aseptic Drug Manufacturing in France

Dishman Carbogen Amcis Limited's subsidiary, Carbogen Amcis SAS, has obtained GMP certification for its new sterile drug product manufacturing facility in Saint-Beauzire, France. The certification follows a successful ANSM inspection and allows for manufacturing and release of clinical and commercial sterile drug products. The 60 million euro facility, opened in 2023, features advanced production lines and complies with latest EU GMP standards. This certification enhances the company's drug product manufacturing capabilities and strengthens its position in offering end-to-end pharmaceutical services.

12Mar 25

Dishman Carbogen Amcis Approves ₹50 Crore Non-Convertible Debenture Issue

Dishman Carbogen Amcis Limited's Board of Directors has approved the issuance of Non-Convertible Debentures (NCDs) worth up to ₹50 crore. The NCDs will be rated, listed, senior, secured, redeemable, and taxable, with a face value of ₹1,00,000 each. The debentures will have a 24-month tenure, a 10% annual coupon rate paid quarterly, and will be listed on the BSE's Wholesale Debt Market Segment. The NCDs will be secured by a first-ranking exclusive charge on a fixed deposit and an exclusive charge on identified freehold land, providing at least 1.25x security cover.

10Mar 25

Dishman Carbogen Amcis to Consider Fund Raising via Non-Convertible Debentures

Dishman Carbogen Amcis Limited has announced a board meeting on March 12 to discuss and potentially approve raising funds through non-convertible debentures (NCDs) via private placement. This move could strengthen the company's financial position without diluting existing shareholders' equity. The decision to explore NCDs suggests the company may be looking to optimize its capital structure or fund specific initiatives.

07Mar 25

Dishman Carbogen Amcis to Consider Fund Raising via NCDs in Upcoming Board Meeting

Dishman Carbogen Amcis Limited has scheduled a board meeting for March 12 to discuss and potentially approve the issuance of non-convertible debentures (NCDs) through private placement. This move indicates the company's strategy to raise funds, possibly for growth initiatives or capital structure management. The outcome of this meeting could significantly impact the company's financial strategy and market perception.